236
Views
3
CrossRef citations to date
0
Altmetric
Reports

Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single center study

, , , , &
Pages 1983-1985 | Received 07 Apr 2021, Accepted 23 Apr 2021, Published online: 23 Mar 2022

References

  • Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519.
  • Carrascosa J, Jacobs I, Petersel D, et al. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther (Heidelb). 2018;8(2):173–194.
  • Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177(6):1495–1502.
  • Generics and Biosimilars Initiative (GaBI). Biosimilars approved in Europe; 2019; [cited 2019 Dec 18]. Available from: http://www.gabio.nline.net/Biosimilars/General/Biosimilars-approved-in-Europe
  • Egeberg A. Real world SB4 (etanercept biosimilar) use in patients with psoriasis: data from British Association of Dermatologist Biologic Interventions Registry (BADBIR): Abstract #P1839. 27th EADV Congress; Paris, France; 2018.
  • Gisondi P, Bianchi L, Conti A, et al. Infliximab biosimilar CTP13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Br J Dermatol. 2017;177(6):e325–e326.
  • Gisondi P, Bianchi L, Calzavara-Pinton P, et al. Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Br J Dermatol. 2019;180(2):409–410.
  • Pescitelli L, Lazzeri L, Di Cesare A, et al. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients. Int J Clin Pharm. 2019;41(1):9–12.
  • Ricceri F, Pescitelli L, Lazzeri L, et al. Clinical experience with infliximab biosimilar in psoriasis. Br J Dermatol. 2017;177(6):e347–e348.
  • Di Cesare A, Tronconi G, Fastame TM, et al. SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2020;33(3):e13435.
  • Zheng J. Absolute Psoriasis Area and Severity Index: an additional evaluation for clinical practice. Br J Dermatol. 2017;176(3):576.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.